Background The nonvitamin K antagonist oral anticoagulants have recently become
available as an alternative to warfarin as stroke prophylaxis in atrial fibrillation, but data on …

Aims Direct oral anticoagulants (DOAC) are progressively replacing vitamin K antagonists in
the prevention of thromboembolism in patients with atrial fibrillation. However, their real …

Introduction Outcomes associated with suboptimal use of antithrombotic treatments
(antiplatelets, warfarin, direct oral anticoagulants [DOACs]) are unclear in Chinese patients …

Background The appropriateness of direct oral anticoagulant (DOAC) dosing has been the
issue in the real-world setting, and inappropriately lower DOAC dose may not be as effective …

Background and Purpose—This ARISTOPHANES study (Anticoagulants for Reduction in
Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients) …

Abstract Introduction Direct oral anticoagulants (DOACs) have seen rapid uptake for the
prevention of stroke associated with non-valvular atrial fibrillation (NVAF). It is unclear …

Background Inappropriate doses of direct oral anticoagulants (DOACs) are often prescribed.
This study evaluated the prevalence, outcomes, and predictors of the prescription of …

Abstract Background Direct oral anticoagulants (DOACs) reduce the risk of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation but may result in serious …

Background Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) are widely used
as stroke prophylaxis in non-valvular atrial fibrillation (AF), but comparative data are sparse …

Background: Direct oral anticoagulants (DOACs) are preferred for stroke prevention in atrial
fibrillation (AF). However, off-label doses have been associated with increased risk of …